Evidence map›Paper›PMID 30197936›Full record

ArticleAdvances in radiation oncology

Updated strategies in the treatment of benign diseases-a patterns of care study of the german cooperative group on benign diseases.

Jan Kriz, Heinrich M Seegenschmiedt, Amelie Bartels, Oliver Micke, Ralph Muecke, Ulrich Schaefer, Uwe Haverkamp, Hans T Eich

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04424628 naunknown statusnot on this map

Three vs Six Gy in Gonarthrosis and Coxarthrosis. Non Inferiority Study

TypeinterventionalSponsorFundacion GenesisCareRan2019 to 2023Enrolled338ConditionsGonarthrosis, CoxarthrosisArmsLow dose radiotherapy A, Low dose radiotherapy B
NCT06104410 naunknown statusnot on this map

Optimization of Fractionation Schedules of Heel Spur Radiotherapy: Monocentric Prospective Randomized Open-label Trial

TypeinterventionalSponsorMasaryk Memorial Cancer InstituteRan2022 to 2025Enrolled430ConditionsHeel SpurArmsStandard fractioned dose, Experimental single dose
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Implementing a low-dose radiation therapy program for musculoskeletal pain disorders: tips, tricks, and essentials for clinical researchers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  9. Low-dose Radiation Therapy (LDRT) in Managing Osteoarthritis: A Comprehensive Review.Current therapeutic research, clinical and experimental · 2025
    Review
  10. Review
  11. Radiotherapy for benign diseases in Turkey: a patterns of care survey of the Turkish Society for Radiation Oncology (TROD 05-002).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  12. Article
  13. Review
  14. The 5Rs dilemma of radiotherapy for non-malignant diseases: 5Rs to darken OR 5Rs to shine.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Review
  15. Review
  16. Analgesic effects of low-dose radiotherapy in greater trochanteric pain syndrome: results in a clinical series of 155 patients with recurrent or refractory symptoms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  17. Treatment of benign tumours and related pathologies with radiotherapy: experience of the General Hospital of Mexico.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jan KrizDepartment of Radiation Oncology, University of Muenster, Muenster, Germany.
Heinrich M SeegenschmiedtRadiation Center Hamburg, Hamburg, Germany.
Amelie BartelsDepartment of Radiation Oncology, University of Muenster, Muenster, Germany.
Oliver MickeDepartment of Radiation Oncology, Franziskus Hospital, Bielefeld, Germany.
Ralph MueckeDepartment of Radiotherapy and Radiation Oncology, Marien Hospital Herne, Ruhr University Bochum, Bochum, Germany.
Ulrich SchaeferDepartment of Radiation Oncology, Klinikum Lemgo, Lemgo, Germany.
Uwe HaverkampDepartment of Radiation Oncology, University of Muenster, Muenster, Germany.
Hans T EichDepartment of Radiation Oncology, University of Muenster, Muenster, Germany.
University of Münster · DEKlinikum Lippe · DESt. Franziskus Hospital · DEUniversitätsklinik Marien Hospital Herne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiation therapy (RT) is a common treatment for benign diseases in Germany. Because the treatment concepts are inconsistent, we conducted this pattern-of-care study on behalf of the German Cooperative Group on Benign Diseases to evaluate treatment standards in Germany. METHODS AND MATERIALS: Questionnaires were mailed to all radiation therapy facilities in Germany. We assessed the treatment equipment, annual number of patients, treatment indications, and, in particular, treatment strategies in patients with benign diseases in 2014.

resultsWe evaluated questionnaires returned by 116 participating institutions, of which 41 were ambulatory health care centers, 28 were private institutions, 27 were community hospitals, and 20 were university hospitals. On average, 2 linac accelerators and 2 megavoltage units were available in each institution. In 2014, a total of 36,830 patients were treated for benign diseases: 16,989 for degenerative diseases (peritendinitis humeroscapularis n = 2691; epicondylitis humeri n = 3788; heel spur n = 10,510); 14,936 for osteoarthritis (coxarthrosis n = 2230; gonarthrosis n = 2623; omarthrosis n = 2691; rhizarthrosis n = 2440; polyarthrosis n = 2297; others n = 2655); 1563 for hyperproliferative diseases (morbus Dupuytren n = 960; morbus Ledderhose n = 441; keloids n = 139; pterygium of the conjunctiva n = 3; other hyperproliferative diseases n = 20); 2440 for functional disorders (gynecomastia n = 843; Graves' disease n = 205; lymphatic fistula n = 178; heterotopic ossification prophylaxis n = 1214); 859 for stereotactic RT in the central nervous system (arteriovenous malformation n = 53; meningioma n = 425; acoustic neuroma n = 201; pituitary adenoma n = 131; others n = 49), and 43 for rare indications (pigmented villonodular synovitis n = 20 or vertebral hemangioma n = 23). The mean whole dose was <10 Gy in the treatment of degenerative disorders, 25 Gy for hyperproliferative diseases, 15 Gy for functional disorders, and <50 Gy for stereotactic RT.

conclusionsIn 2014, RT had an important role in the treatment of benign diseases. Because treatment concepts are inherent, we recommend treatment based on the guidelines written by the German Cooperative Group on Benign Diseases.

Identifiers

PMID30197936
PMCPMC6127969
OpenAlexW2529331458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.